Candel Therapeutics Inc
Save
370.04M
Market cap
–
Current P/E
44.05x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.
Similar securities
Based on sector and market capitalization
Report issue